India, Aug. 19 -- Basilea Pharmaceutica Ltd (BSLN.SW) has updated its 2025 financial guidance, projecting higher total revenue following the recent in-licensing of a novel, oral, Phase 3-ready antibiotic.
The company expects that annual total revenue will increase by 8% to 225 million Swiss francs. It expects to maintain a high operating profit level of 50 million francs in 2025.
The company expects no material cash outflow related to income taxes as a result of the use of tax loss carry forwards, but a 10.7% income tax expense will be reflected in the 2025 net profit, in contrast to a 17.3 million francs one-time income tax benefit from releasing the deferred tax valuation allowance in 2024.
Basilea reported that its net profit for the ...